Best Immunotherapy Companies in Shanghai, China
The 38 best Immunotherapy companies in Shanghai, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CStone Pharma.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Shanghai
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | CStone Pharma Developing and licensing novel drugs for diseases including cancer and autoimmune diseases | $410M | 71 mo ago | 476 | — | Public | — | 1 partnership |
| 2 | Tianjing Biological Developer of immuno-oncology drugs for treating cancer and autoimmune diseases 55Funding top 21%Market top 41%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 21% Markettop 41% Moattop 48% Talentbottom 49% Globalbottom 46% Techbottom 45% Newsbottom 21% Funding: Raised $380M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Market: 318 employees (top 5% of Life Sciences) · Top-10,000,000 web property rank vs industry peers · Fliar Intelligence Index 55/100 | $380M | 31 mo ago | 318 | Yan Jingwu Chairman & CEO | Public | — | — |
| 3 | Harbour BioMed Developer of antibody therapeutics in immunology and oncology disease | $313M | 74 mo ago | 167 | Jingsong Wang Founder | Public | 248 patents Bispecific antibody therapeutics targeting immune checkpoints and tumor antigens | 1 partnership |
| 4 | CARsgen Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors | $276M | 70 mo ago | 525 | Huamao Wang Co-Founder & COO | Public | — | — |
| 5 | Abbisko Therapeutics Developing novel small molecule drugs for immunomodulatory pathways to treat cancer | $263M | 68 mo ago | 252 | — | Public | 309 patents Small‑molecule kinase inhibitors targeting FGFR4, CSF‑1R, CDK, CD73, and PARP for cancer therapy | — |
| 6 | D3 Bio Developer novel therapeutics for cancer 40Funding top 20%Growth top 35%Talent bottom 49%Moat bottom 48% All 7 signals ▾Fundingtop 20% Growthtop 35% Talentbottom 49% Moatbottom 48% Techbottom 40% Globalbottom 38% Marketbottom 28% Funding: Raised $262M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $262M | 9 mo ago | — | George Chen Founder & CEO | Series B | — | — |
| 7 | Elpiscience Developer of checkpoint inhibitors for the treatment of cancer | $260M | 64 mo ago | 150 | — | Series C | — | — |
| 8 | EpimAb Biotherapeutics Bispecific antibody therapies using its proprietary FIT-Ig platform | $219M | 65 mo ago | 49 | — | Series C | 123 patents Bispecific antibody therapeutics targeting immune checkpoints and tumor antigens for cancer immunotherapy | — |
| 9 | Genor Biopharma Developer of biosimilar monoclonal antibodies for treating multiple diseases | $216M | 75 mo ago | 222 | — | Public | 45 patents Bispecific/trispecific immune checkpoint antibodies for cancer immunotherapy | — |
| 10 | JW Therapeutics Developer of cell immunotherapy products for cancer treatment | $200M | 74 mo ago | 490 | James Li Co-Founder & CEO | Public | 34 patents Small-molecule KRAS G12C mutant protein inhibitors for targeted cancer therapy | — |
| 11 | Gracell Bio Developer of CAR T cell therapies for the treatment of cancer | $195M | 37 mo ago | 9 | Wei Cao Founder & CEO | Acquired | — | — |
| 12 | OriCell Therapeutics Developer of immuno-therapeutics for cancer treatment 72Funding top 16%Patents top 27%Moat top 28%Innovation top 34% All 8 signals ▾Fundingtop 16% Patentstop 27% Moattop 28% Innovationtop 34% Newstop 36% Markettop 37% Talentbottom 49% Globalbottom 43% Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $170M | 5 mo ago | 150 | He Xiaowen Co-Founder | Series D | 56 patents Patents concentrated in health & consumer products | — |
| 13 | Zai Lab Developer of drugs for anti-cancer and anti-inflammatory diseases | $160M | 110 mo ago | 2,036 | — | Public | 49 patents Antibody therapeutics targeting CCR8/IL‑31Rα and small‑molecule TEAD & PARG inhibitors for cancer immunotherapy | — |
| 14 | TYK Medicines Developer of drugs for the treatment of cancer | $154M | 32 mo ago | 100 | Wu Yusheng Founder & CEO | Public | 164 patents Small‑molecule kinase inhibitor drugs and their crystal/formulation innovations for oncology | — |
| 15 | ImmuneOnco Biopharmaceuticals Developer of therapeutic solutions for treating cancer | $146M | 65 mo ago | 152 | Tian Wenzhi Founder & CEO | Public | 74 patents Recombinant fusion proteins and antibodies targeting immune checkpoints and angiogenic/CD antigens for cancer therapy | — |
| 16 | Duality Biologics Developer of ADC therapeutics to treat cancer and autoimmune diseases | $120M | 63 mo ago | — | John Zhu Founder&Ceo | Public | 136 patents Targeted antibody-drug conjugates and bispecific antibodies with novel linker chemistries | — |
| 17 | Innovative Cellular Therapeutics Developer of CAR-T cell therapies for blood cancers and solid tumors | $97M | 60 mo ago | 14 | Lei Xiao CEO | Series C | 73 patents Engineered immune cell therapies: CAR‑T, PD‑L1 modulation, cell expansion, therapeutic gene delivery | — |
| 18 | Inxmed Developer of treatments for drug resistance and metastases in solid tumors | $84M | 49 mo ago | 50 | Francis Cao Co-Founder | Series B | — | — |
| 19 | GRIT Biotechnology Developer of cell therapy to treat solid tumours | $75M | 36 mo ago | — | Liu Yarong Founder & CEO | Series B | 56 patents Engineered immune cells and bispecific proteins for targeted cancer immunotherapy | — |
| 20 | Phrontline Biopharma Developer of therapeutics for various diseases 64Talent top 28%Funding top 29%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 29% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $60M | 9 mo ago | — | Siyi Hu Co-Founder | Seed | — | — |
| 21 | NUTSHELL Developer of small molecule-based therapeutic solutions for the treatment of cancer | $60M | 54 mo ago | — | Zhengtian Yu Co-Founder & CTO | Series A | — | — |
| 22 | Mab venture Early stage company developing therapeutic antibodies | $35M | 101 mo ago | — | George Wang CEO & Founder | Deadpooled | 5 patents LAG-3 immune checkpoint antibody therapeutics for cancer immunotherapy | — |
| 23 | Junshi BioPharma Provider of antibody-based therapeutics for multiple diseases | $31M | 102 mo ago | 2,772 | — | Public | — | — |
| 24 | Conjustar Developer of drug conjugates for the treatment of cancer | $28M | 31 mo ago | — | Shuyi Tang CEO | Seed | — | — |
| 25 | ITabMed Developer of immunotherapeutics to treat cancer | $20M | 57 mo ago | — | Xiaoqiang Yan CEO | Series A | 5 patents Bispecific antibody therapeutics targeting CD19 and CD3 for cancer immunotherapy | — |
| 26 | Nk-Celltech Provider of immuno-oncologic drugs for cancer 40Market top 45%Funding top 46%Global bottom 38% All 3 signals ▾Markettop 45% Fundingtop 46% Globalbottom 38% Market: 60 employees (top 31% of Life Sciences) Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $15M | 14 mo ago | 60 | — | Series A | — | — |
Top 12 Immunotherapy companies in Shanghai
#1
Series D · Pudong, Shanghai · founded 2015 · 150 employees$170Mraised▾
Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.
- Apr 2026Series D$110M
- Jan 2026Series C$70M
- Feb 2023Series B$45M
- Aug 2022Series B$125M
#2
Series B · Shanghai, Shanghai · founded 2018$262Mraised▾
Developer novel therapeutics for cancer. The company is focusing on developing innovative medicines in oncology and immunology. The company's pipeline include D3S-001 for the treatment of advanced unresectable or metastatic colorectal cancers.
- Dec 2025Series B$108M
- Apr 2024Series A$62M
- Nov 2020Series A$200M
#3
Seed · Pudong, Shanghai · founded 2022$60Mraised▾
Developer of therapeutics for various diseases. It offers a proprietary dual linker payload ADCs that are delivered to and concentrated in the tumor microenvironment, and bispecific dual payload ADCs that have the benefits of dual targeting that dilever two different MOA of payloads to cancel cells simultaneously.
- Nov 2025Seed$60M
#4
Series A · Pudong, Shanghai · founded 2020 · 60 employees$14.9Mraised▾
Provider of NK cell therapy for treating cancer, cellular drugs to precisely target of tumors and tumor immune microenvironment (TIME)
- Jul 2025Series A$13.9M
- Jul 2022Series A$14.9M
#5
Public · Shanghai, Shanghai · founded 2014 · 318 employees$380Mraised▾
Developer of immuno-oncology drugs for treating cancer and autoimmune diseases. The company has developed an in-house platform to generate monoclonal antibodies through hybridoma and phage display technologies. The company's product line include Olamkicept used for treating ulcerative colitis, TJ202 for Multiple myeloma / Autoimmune diseases, TJ101 for pediatric growth hormone deficiency, TJ301 for Ulcerative colitis / Auto-immune disease, Enoblituzumab for T cell activation combined with tumor-killing, etc.
- Feb 2024Post IPO$69.9M
- Sep 2020Post IPO$418M
- Jun 2018Series C$220M
- Mar 2017Series B$150M
#6
Public · Xuhui, Shanghai · founded 2018 · 100 employees$153.6Mraised▾
Developer of drugs for the treatment of cancer. The company's products include TY-9591 is used to treat brain metastasis, TY-302 is used to treat solid tumours and ovarian cancer, TY-2136 is used for NSCLC, and TY-1036 is for MTC and NSCLC. These drugs can also be used with the combination of other drugs to treat cancer and other solid tumours.
- Dec 2023Series D—
- Jan 2022Series C$51.7M
- May 2021Series B$62.1M
- Dec 2020Series B$39.8M
#7
Acquired · Shanghai, Shanghai · founded 2017 · 9 employees$195.2Mraised▾
Developer of CAR T cell therapies for the treatment of cancer. The company has developed a gene-editing platform to produce multiplex CAR T cell therapies such as FasTCAR, TruUCAR, and Donor-derived CAR for multiple myeloma, lymphoma, and leukemia. The company is also working on a combination of CAR-T with co-stimulatory factors.
- Aug 2023Post IPO—
- Oct 2020Series C$100M
- Feb 2019Series B$85M
- Sep 2018Series A$10.2M
#8
Series B · Shanghai, Shanghai · founded 2020$75.3Mraised▾
Developer of cell therapy to treat solid tumours. The company uses Tumor Infiltration Lymphocytes (TIL) for the development of tumour immunotherapy. TIL is a tumour-specific killer T-cell which targets multiple tumour antigens in the tumour microenvironment.
- Sep 2023Series B$60M
- Dec 2020Series A$15.3M
#9
Public · Shanghai, Shanghai · founded 2016 · 476 employees$410Mraised▾
CStone Pharma, a Shanghai-Suzhou startup, is developing and licensing novel drugs with a focus on immuno-oncology along with drugs for cardiovascular diseases, hematology and autoimmune diseases (e.g - rheumatoid arthritis). It has a robust oncology pipeline with eight assets in clinical stages. It is working on various targets including IDHm1, PDL-1, FGFR4, RET, PD-1, etc. The lead molecule, TIBSOVO has got FDA approval.
- Sep 2020Post IPO$200M
- May 2018Series B$260M
- Jul 2016Series A$150M
#10
Seed · Shanghai, Shanghai · founded 2022$27.8Mraised▾
Developer of drug conjugates for the treatment of cancer. The company is developing miniaturized drug conjugates such as peptide, nanobody drug conjugates, and PDC to conquer solid tumors.
- Jan 2024Seed$12.6M
- Feb 2023Angel$8M
- Feb 2022Seed$7.2M
#11
Series C · Pudong, Shanghai · founded 2017 · 150 employees$260Mraised▾
Elpiscience is developing immunotherapies for cancer. The company has its pipeline which includes in-house and partnership projects. The lead candidate, ES 101 is a bispecific antibody targeting 4-1BB and PD-L1 (preclinical stage). The molecule is developed by Inhibrx and the company has Chinese rights. Another candidate, ES001 is an anti-TIM-3 antibody, developed by Enumeral.
- May 2021Series C$105M
- Dec 2019Series B$100M
- Dec 2018Series A$35M
- 2017Series A$20M
#12
Public · Shanghai, Shanghai · founded 2016 · 167 employees$312.8Mraised▾
Developer of antibody therapeutics in immunology and oncology disease. The products Batoclimab for the treatment of autoimmune diseases, Tanfanercept for the treatment of dry eye disease, HBM4003, HBM9022, to prevent and treat COVID-19, and various candidates for treating solid tumors, myeloma, and cancer. The company has a Harbour Mice, HBICE, and single-cell technology platform to generate fully human monoclonal antibodies.
- Jul 2020Series C$102.8M
- Mar 2020Series B$75M
- Aug 2018Series B$85M
- Jan 2018Series B—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology in Shanghai is moving
A read on the academic research around Immunology in Shanghai — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,243 papers.
- Shanghai Jiao Tong University375
- Fudan University Shanghai Cancer Center175
- Shanghai University of Traditional Chinese Medicine120
- Shanghai Medical College of Fudan University107
- Shanghai Cancer Institute73
- Immunotherapy2→230
- Immune system1→210
- Cancer research1→82
- Cancer immunotherapy1→79
- Immune checkpoint2→26
- Immunotherapy3→299
- Immune system1→254
- Tumor microenvironment2→109
- Cancer research3→91
- Oncology1→60
- Immunotherapy1→69
- Immune system2→39
- Cancer1→23
- Cancer immunotherapy1→14
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.